NVRO Stock Forecast 2025-2026
Distance to NVRO Price Targets
NVRO Price Momentum
🤔 Considering Nevro (NVRO)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest NVRO Stock Price Targets & Analyst Predictions
Based on our analysis of 25 Wall Street analysts, NVRO has a neutral consensus with a median price target of $5.85 (ranging from $4.70 to $13.00). The overall analyst rating is Hold (5.8/10). Currently trading at $5.80, the median forecast implies a 0.9% upside. This outlook is supported by 0 Buy, 12 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Nathan Treybeck at Wells Fargo, projecting a 124.1% upside. Conversely, the most conservative target is provided by Richard Newitter at Truist Securities, suggesting a 19.0% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NVRO Analyst Ratings
NVRO Price Target Range
Latest NVRO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NVRO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 7, 2025 | Piper Sandler | Adam Maeder | Neutral | Upgrade | $5.85 |
| Feb 7, 2025 | Canaccord Genuity | William Plovanic | Hold | Maintains | $5.85 |
| Dec 18, 2024 | Truist Securities | Richard Newitter | Hold | Maintains | $4.70 |
| Dec 11, 2024 | Wells Fargo | Nathan Treybeck | Equal-Weight | Maintains | $4.00 |
| Dec 11, 2024 | Citigroup | Joanne Wuensch | Neutral | Maintains | $5.00 |
| Dec 9, 2024 | Canaccord Genuity | William Plovanic | Hold | Maintains | $4.00 |
| Dec 3, 2024 | Wells Fargo | Nathan Treybeck | Equal-Weight | Reinstates | $5.00 |
| Dec 2, 2024 | Morgan Stanley | Cecilia Furlong | Underweight | Downgrade | $4.00 |
| Nov 12, 2024 | JMP Securities | David Turkaly | Market Perform | Reiterates | $0.00 |
| Nov 12, 2024 | Canaccord Genuity | William Plovanic | Hold | Maintains | $7.00 |
| Nov 12, 2024 | RBC Capital | Shagun Singh | Sector Perform | Reiterates | $7.00 |
| Nov 12, 2024 | Piper Sandler | Adam Maeder | Underweight | Maintains | $6.00 |
| Nov 12, 2024 | Baird | Mike Polark | Neutral | Maintains | $6.00 |
| Oct 1, 2024 | Citigroup | Joanne Wuensch | Neutral | Maintains | $6.00 |
| Aug 9, 2024 | Citigroup | Joanne Wuensch | Neutral | Upgrade | $6.89 |
| Aug 8, 2024 | Wolfe Research | Mike Polark | Peer Perform | Upgrade | $0.00 |
| Aug 8, 2024 | Truist Securities | Richard Newitter | Hold | Maintains | $5.50 |
| Aug 7, 2024 | RBC Capital | Shagun Singh | Sector Perform | Maintains | $7.00 |
| Aug 7, 2024 | Piper Sandler | Adam Maeder | Underweight | Maintains | $7.00 |
| Aug 7, 2024 | Wells Fargo | Nathan Treybeck | Underweight | Downgrade | $5.50 |
Nevro Corp. (NVRO) Competitors
The following stocks are similar to Nevro based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Nevro Corp. (NVRO) Financial Data
Nevro Corp. has a market capitalization of $222.56M with a P/E ratio of 144.4x. The company generates $408.52M in trailing twelve-month revenue with a -27.8% profit margin.
Revenue growth is -9.1% quarter-over-quarter, while maintaining an operating margin of -21.8% and return on equity of -43.3%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Nevro Corp. (NVRO) Business Model
About Nevro Corp.
Develops innovative solutions for chronic pain management.
Nevro Corp. generates revenue by selling its flagship Senza Spinal Cord Stimulation system, which provides advanced neuromodulation solutions for chronic pain relief. The company targets patients with persistent pain who have not found relief through traditional treatments, thereby positioning itself in a niche market within the healthcare sector.
Nevro is committed to research and development, aiming to improve the efficacy of its pain management solutions and enhance patient outcomes. The company has established a strong reputation in the medical device industry and continues to innovate in neuromodulation therapies.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
1,099
CEO
Mr. Kevin R. Thornal
Country
United States
IPO Year
2014
Website
nevro.comNevro Corp. (NVRO) Latest News & Analysis
NVRO's Q4 earnings exceeded estimates, but worldwide revenues fell year-over-year, and the company continues to report operating losses.
NVRO's earnings beat estimates but declining revenues and ongoing operating losses highlight potential concerns about future growth and profitability, influencing investor sentiment.
Nevro (NVRO) reported a quarterly loss of $0.64 per share, better than the expected loss of $0.79, but worse than a loss of $0.15 per share from the same quarter last year.
Nevro's smaller-than-expected loss indicates improved performance, potentially boosting investor confidence and impacting stock valuation positively.
Nevro Corp. (NYSE: NVRO) announced its fourth-quarter and full-year 2024 financial results on March 4, 2025, as part of its focus on chronic pain treatment solutions.
Nevro's Q4 and full-year 2024 results will provide insights into its financial health and growth trajectory, influencing stock performance and investor sentiment in the medical device sector.
The Ademi Firm is investigating Nevro (NYSE: NVRO) for potential fiduciary duty breaches related to its transaction with Globus Medical.
The investigation into Nevro for potential fiduciary breaches could lead to legal issues, affecting its stock performance and investor confidence.
Nevro (NVRO) is anticipated to exceed earnings expectations in its upcoming report, driven by two key favorable factors.
Nevro's potential for an earnings beat signals strong performance, which can boost stock prices and investor confidence, impacting overall market sentiment and investment decisions.
Kahn Swick & Foti, LLC is investigating the proposed sale of Nevro Corp. (NYSE: NVRO) to Globus Medical, Inc. (NYSE: GMED), where shareholders would receive $5.85 per share.
The investigation into Nevro Corp.'s sale to Globus Medical may impact share prices and the perceived value of the acquisition, signaling potential risks or opportunities for investors.
Frequently Asked Questions About NVRO Stock
What is Nevro Corp.'s (NVRO) stock forecast for 2025?
Based on our analysis of 25 Wall Street analysts, Nevro Corp. (NVRO) has a median price target of $5.85. The highest price target is $13.00 and the lowest is $4.70.
Is NVRO stock a good investment in 2025?
According to current analyst ratings, NVRO has 0 Buy ratings, 12 Hold ratings, and 1 Sell ratings. The stock is currently trading at $5.80. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NVRO stock?
Wall Street analysts predict NVRO stock could reach $5.85 in the next 12 months. This represents a 0.9% increase from the current price of $5.80. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Nevro Corp.'s business model?
Nevro Corp. generates revenue by selling its flagship Senza Spinal Cord Stimulation system, which provides advanced neuromodulation solutions for chronic pain relief. The company targets patients with persistent pain who have not found relief through traditional treatments, thereby positioning itself in a niche market within the healthcare sector.
What is the highest forecasted price for NVRO Nevro Corp.?
The highest price target for NVRO is $13.00 from Nathan Treybeck at Wells Fargo, which represents a 124.1% increase from the current price of $5.80.
What is the lowest forecasted price for NVRO Nevro Corp.?
The lowest price target for NVRO is $4.70 from Richard Newitter at Truist Securities, which represents a -19.0% decrease from the current price of $5.80.
What is the overall NVRO consensus from analysts for Nevro Corp.?
The overall analyst consensus for NVRO is neutral. Out of 25 Wall Street analysts, 0 rate it as Buy, 12 as Hold, and 1 as Sell, with a median price target of $5.85.
How accurate are NVRO stock price projections?
Stock price projections, including those for Nevro Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
